| 1 |
dpavlin |
1.1 |
50 PLIVA and Microsoft sign global purchasing agreement</a></b><br> |
| 2 |
|
|
<i>Zagreb, 18 January 2001.</i><br> |
| 3 |
|
|
PLIVA and Microsoft signed the Microsoft Enterprise |
| 4 |
|
|
Agreement - an agreement lasting several years which enables PLIVA to standardise |
| 5 |
|
|
Microsoft technology on its computers in facilities in Croatia and throughout Central |
| 6 |
|
|
and Eastern Europe. |
| 7 |
|
|
|
| 8 |
|
|
49 PLIVA acquires Dominion</a></b><br> |
| 9 |
|
|
<i>Zagreb, 19 December 2000.</i><br> |
| 10 |
|
|
PLIVA d.d. ("PLIVA") announced today that is has acquired Pharmascience UK |
| 11 |
|
|
Limited, 100% owner of Dominion Pharma Limited ("Dominion"), for |
| 12 |
|
|
a total cash consideration of GBP 3.4 million. |
| 13 |
|
|
|
| 14 |
|
|
48 PLIVA and Zagrebacka banka Agreement</a></b><br> |
| 15 |
|
|
<i>Zagreb, 19 December 2000.</i><br> |
| 16 |
|
|
PLIVA d.d. (PLIVA) and Zagrebacka banka (ZABA) today announced that they have |
| 17 |
|
|
reached an agreement regarding the sale of ZABA's 2.5% equity stake in PLIVA. |
| 18 |
|
|
|
| 19 |
|
|
47 VETERINA d.o.o. Established</a></b><br> |
| 20 |
|
|
<i>Zagreb, 8 December 2000.</i><br> |
| 21 |
|
|
Based on strategic orientation to pharmaceuticals as its core business, PLIVA has |
| 22 |
|
|
decided to spin off its Animal Health & Agrochemicals business segment into an |
| 23 |
|
|
independent company in its full ownership. |
| 24 |
|
|
|
| 25 |
|
|
46 Engineer from PLIVA wins golden award for innovation</a></b><br> |
| 26 |
|
|
<i>Zagreb, 8 December 2000.</i><br> |
| 27 |
|
|
PLIVA's employee Srecko Brkic, a mechanical engineer in Technical Operations, won |
| 28 |
|
|
the golden award at the 49th World Fair of Innovation, Research and New Technologies |
| 29 |
|
|
EUREKA 2000 |
| 30 |
|
|
|
| 31 |
|
|
45 Simplified customs procedures for the company</a></b><br> |
| 32 |
|
|
<i>Zagreb, 8 December 2000.</i><br> |
| 33 |
|
|
Today PLIVA started implementing simplified customs procedures, granted to the company |
| 34 |
|
|
as part of a pilot-project by the Customs Administration of the Republic of Croatia. |
| 35 |
|
|
|
| 36 |
|
|
44 PLIVA s R&D Day in London on November 29, 2000 Balanced Portfolio for Short, Medium and Long Term Growth</a></b><br> |
| 37 |
|
|
<i>Zagreb, 29 November 2000.</i> |
| 38 |
|
|
|
| 39 |
|
|
43 PLIVA signs USD 85 m Credit Facility Agreement with EBRD and IFC</a></b><br> |
| 40 |
|
|
<i>Zagreb, 20 November 2000.</i><br> |
| 41 |
|
|
PLIVA d.d.(PLIVA) today announced that it signed a credit facility agreement |
| 42 |
|
|
(The Agreement) with the European Bank for Reconstruction and Development (EBRD) |
| 43 |
|
|
and the International Finance Corporation (IFC) on 17 November 2000. |
| 44 |
|
|
|
| 45 |
|
|
42 PLIVA's subsidiary NEVA d.o.o. obtains the ISO 14001 environmental management system certification</a></b><br> |
| 46 |
|
|
<i>Zagreb, 15 November 2000.</i><br> |
| 47 |
|
|
In the presence of Mr. Roland Zuvanic, Deputy Minister of Environmental Protection |
| 48 |
|
|
and Zoning, and Mr. Zeljko Covic, President of the Management Board and CEO of PLIVA, |
| 49 |
|
|
Mr. Leonardo Omodeo-Zorini, representative of the Norwegian certification company DNV |
| 50 |
|
|
presented the certificate to NEVA's director Ms. Sanja Slunjski. |
| 51 |
|
|
|
| 52 |
|
|
41 Encouragement to young scientists</a></b><br> |
| 53 |
|
|
<i>Zagreb, 14 November 2000.</i><br> |
| 54 |
|
|
On 14 November 2000 PLIVA and the Croatian Chemical Society presented |
| 55 |
|
|
the Organic Chemistry Award Vladimir Prelog for the fourth time. This year |
| 56 |
|
|
the award was presented to Valerije Vrcek, Ph.D., a young scientist from |
| 57 |
|
|
the Faculty of Pharmacy and Biochemistry in Zagreb. |
| 58 |
|
|
|
| 59 |
|
|
40 State and business delegation from Turkey visits PLIVA</a></b><br> |
| 60 |
|
|
<i>Zagreb, 28 September 2000.</i><br> |
| 61 |
|
|
A state and business delegation from Turkey was in an official visit to Zagreb from 26 to 28 |
| 62 |
|
|
September 2000. The delegation was led by Minister of Health of the Republic of Turkey, Mr. Osman Durmus. |
| 63 |
|
|
|
| 64 |
|
|
39 PLIVA divests Lachema's non-core operations in Blansko</a></b><br> |
| 65 |
|
|
<i>Zagreb, 11 September 2000.</i><br> |
| 66 |
|
|
PLIVA d.d. ('PLIVA') announced today that it has signed an agreement with Synthon s.r.o., |
| 67 |
|
|
subsidiary of the Dutch firm Synthon BV, regarding the sale of Lachema's |
| 68 |
|
|
non-core operations in Blansko, Czech Republic. |
| 69 |
|
|
|
| 70 |
|
|
|
| 71 |
|
|
38 A New Mandate for the Members of PLIVA's MB</a></b><br> |
| 72 |
|
|
<i>Zagreb, 7 September 2000.</i><br> |
| 73 |
|
|
As the mandates of PLIVA's Management Board members are expiring, the company's |
| 74 |
|
|
Supervisory Board appointed the Management Board members for a new five-year period. |
| 75 |
|
|
|
| 76 |
|
|
37 PLIVA's Scientists - Heroes of Chemistry</a></b><br> |
| 77 |
|
|
<i>Zagreb, 20 August 2000.</i><br> |
| 78 |
|
|
The "Heroes of Chemistry |
| 79 |
|
|
2000"ceremony was held on 20 August 2000 in Washington D.C., USA, organised |
| 80 |
|
|
by the American Chemical Society (ACS), a non-profit association of American |
| 81 |
|
|
chemists and chemical engineers and the largest association of scientists in the |
| 82 |
|
|
world. |
| 83 |
|
|
|
| 84 |
|
|
36 Special Announcement</a></b><br> |
| 85 |
|
|
<i>Zagreb, 18 July 2000.</i><br> |
| 86 |
|
|
We would like to inform you that |
| 87 |
|
|
PLIVA's annual summer holiday will last from July 24th to August 14th. |
| 88 |
|
|
|
| 89 |
|
|
35 PLIVA to reduce workforce by the end of 2000</a></b><br> |
| 90 |
|
|
<i>Zagreb, 3 July 2000.</i><br> |
| 91 |
|
|
PLIVA d.d. ('PLIVA') announced today that it will significantly reduce its total |
| 92 |
|
|
workforce by the end of the year. |
| 93 |
|
|
|
| 94 |
|
|
34 PLIVA's Annual General Meeting</a></b><br> |
| 95 |
|
|
<i>Zagreb, 8 June 2000.</i><br> |
| 96 |
|
|
The General Assembly of PLIVA d.d. shareholders was held today. The PLIVA Management Board presented Company's 1999 |
| 97 |
|
|
operations and position, while the Supervisory Board gave a presentation on |
| 98 |
|
|
their monitoring of the Company's management of affairs. |
| 99 |
|
|
|
| 100 |
|
|
33 PLIVA Granted License for an Anti-Fungal NCE by BAYER AG</a></b><br> |
| 101 |
|
|
<i>Zagreb, 23 May 2000.</i><br> |
| 102 |
|
|
PLIVA d.d. ('PLIVA') announced today that it has received a license |
| 103 |
|
|
for a new chemical entity for the treatment of fungal infections from |
| 104 |
|
|
BAYER AG, Germany, a compound in its final stage of pre-clinical |
| 105 |
|
|
trials. |
| 106 |
|
|
|
| 107 |
|
|
32 Chinese Minister of Health Visits PLIVA</a></b><br> |
| 108 |
|
|
<i>Zagreb, 20 May 2000.</i><br> |
| 109 |
|
|
A high-level delegation headed by Mr. Zhang Wenkang, Minister of Health of |
| 110 |
|
|
The People's Republic of China, is visiting Croatia. The Mr. Wenkang's |
| 111 |
|
|
visit has been organised by the Croatian Ministry of Health and the |
| 112 |
|
|
Chinese Embassy. |
| 113 |
|
|
|
| 114 |
|
|
31 Additional Stake Acquired in Lachema</a></b><br> |
| 115 |
|
|
<i>Zagreb, 27 April 2000.</i><br> |
| 116 |
|
|
PLIVA announced today that it has |
| 117 |
|
|
signed an agreement with an institutional investor for the purchase of 26.08% of |
| 118 |
|
|
the total share capital of Lachema, the Czech pharmaceutical company, for cash |
| 119 |
|
|
consideration of USD 4,945,308.49. |
| 120 |
|
|
|
| 121 |
|
|
30 PLIVA Group 1999 Full Year Results</a><br> |
| 122 |
|
|
<i>Zagreb, 23 March 2000.<br> |
| 123 |
|
|
With a 26.2% growth in net |
| 124 |
|
|
income to HRK 869.1 m, PLIVA achieved strong operating results in 1999, |
| 125 |
|
|
despite unfavourable conditions in the surrounding region. |
| 126 |
|
|
|
| 127 |
|
|
29 PLIVA sells 75% stake in its Yeast Subsidiary<br> |
| 128 |
|
|
</b><i>Zagreb, March 1, 2000.</i><br> |
| 129 |
|
|
PLIVA d.d. ('PLIVA') announced that it has signed an |
| 130 |
|
|
agreement to sell its yeast operations carried out through its Croatian |
| 131 |
|
|
subsidiary SAF Kvasac d.o.o. to Cie des Levures Lesaffre, todays world leader |
| 132 |
|
|
in the production of yeast and yeast extracts. |
| 133 |
|
|
|
| 134 |
|
|
28 New drug forms and prices</a><br> |
| 135 |
|
|
</b><i>Zagreb, 15 February 2000.</i><br> |
| 136 |
|
|
The Croatian Institute |
| 137 |
|
|
for Health Insurance has announced its reimbursment list as of 15 February 2000. |
| 138 |
|
|
This includes five new drug forms produced by PLIVA |
| 139 |
|
|
|
| 140 |
|
|
27 PLIVA ups stake in PLIVA Krakow</a><br> |
| 141 |
|
|
</b><i>Zagreb, December 16, 1999.</i><br> |
| 142 |
|
|
PLIVA today announced that it has acquired |
| 143 |
|
|
an additional 6.17 per cent share capital of PLIVA Krakow S.A. from |
| 144 |
|
|
Handlowy Investments S.A., for a cash consideration of USD 16,008,726.29. |
| 145 |
|
|
|
| 146 |
|
|
26 Management Board Changes</a><br> |
| 147 |
|
|
</b><i>Zagreb, December 9, 1999.</i><br> |
| 148 |
|
|
The organisational changes resulting from the PLIVA XXI project and the |
| 149 |
|
|
further internationalisation of the Companys activities entail changes |
| 150 |
|
|
in the roles and responsibilities of the members of the Management Board. |
| 151 |
|
|
|
| 152 |
|
|
25 Y2k Preparations</a><br> |
| 153 |
|
|
<i>Zagreb, 6 December 1999.<br> |
| 154 |
|
|
We at PLIVA |
| 155 |
|
|
d.d. are fully aware of the need for Y2k compliance to avoid any business |
| 156 |
|
|
disruption associated with computer software, hardware and embedded |
| 157 |
|
|
systems that are incapable of managing dates beyond the year 1999. |
| 158 |
|
|
|
| 159 |
|
|
24 Lachema Acquisition Finalised</a><br> |
| 160 |
|
|
</b><i>Zagreb, December 3, 1999.</i><br> |
| 161 |
|
|
PLIVA today announced that the acquisition of 66,67% stake of the Czech pharmaceutical |
| 162 |
|
|
company, Lachema, was completed yesterday when PLIVA Krakow, PLIVAs |
| 163 |
|
|
subsidiary paid agreed price of USD 26.5 million. |
| 164 |
|
|
|
| 165 |
|
|
23 PLIVA Acquires Czech Lachema</a><br> |
| 166 |
|
|
<i>Zagreb, 12 November 1999.<br> |
| 167 |
|
|
</i>PLIVA |
| 168 |
|
|
has announced that it has signed agreements for the purchase of a 66.67% |
| 169 |
|
|
stake in Lachema, the Czech pharmaceutical company, for a cash |
| 170 |
|
|
consideration of USD 26.5 million from the companys institutional |
| 171 |
|
|
investors. |
| 172 |
|
|
|
| 173 |
|
|
22 Notice to PLIVA d.d. Shareholders</a><br> |
| 174 |
|
|
<i>Zagreb, 26 October 1999.<br> |
| 175 |
|
|
</i>According |
| 176 |
|
|
to the decision of the General Assembly of PLIVA d.d. shareholders held on 03 |
| 177 |
|
|
June 1999 concerning distribution of dividends to shareholders, PLIVA d.d. |
| 178 |
|
|
should pay the 1998 dividend not later than 31 December 1999. |
| 179 |
|
|
|
| 180 |
|
|
21 Predrag Novak Receives Phys. Chem. Award</a><br> |
| 181 |
|
|
<i>Zagreb, 26 October 1999.<br> |
| 182 |
|
|
The |
| 183 |
|
|
award presented each year by the Croatian Chemical Society for |
| 184 |
|
|
achievements in the field of physical chemistry was presented to Predrag |
| 185 |
|
|
Novak, Ph.D., who works in PLIVAs Research Institute, at a ceremony |
| 186 |
|
|
held at the Rudjer Boskovic Institute on Tuesday, October 19th. |
| 187 |
|
|
|
| 188 |
|
|
|
| 189 |
|
|
20 PLIVA Facilities Pass FDA Inspection</a><br> |
| 190 |
|
|
</b><i>Zagreb, 27 October 1999.</i><br> |
| 191 |
|
|
PLIVAs new Azithromycin facility was found to be in compliance with good |
| 192 |
|
|
manufacturing practice according to the Food and Drug Administration (FDA) inspection carried out |
| 193 |
|
|
in mid-October of 1999. |
| 194 |
|
|
|
| 195 |
|
|
|
| 196 |
|
|
19 Virlix® Price Approval Application at PLIVA-Krakow.</a><br> |
| 197 |
|
|
<i>Zagreb, 14 October 1999.<br> |
| 198 |
|
|
PLIVA Krakow has applied for price approval of the drug Virlix® |
| 199 |
|
|
10mg*20tab. (cetirizine) which will replace the product Zyrtec® |
| 200 |
|
|
10mg*20tab. (cetirizine) in PLIVA Krakows product portfolio. |
| 201 |
|
|
|
| 202 |
|
|
18 Successful Debt Collection and the VAT</a><br> |
| 203 |
|
|
</b><i>Zagreb, 14 October 1999.</i><br> |
| 204 |
|
|
As |
| 205 |
|
|
a result of a restrictive sales policy and higher collection from the |
| 206 |
|
|
healthcare sector, in the last three months, PLIVA has recorded a decrease |
| 207 |
|
|
in receivables from the Croatian healthcare sector, from HRK 613 million |
| 208 |
|
|
at the end of June 1999 to HRK 400 million to date. |
| 209 |
|
|
|
| 210 |
|
|
17 Vladimir Prelog Organic Chemistry Award.</a><br> |
| 211 |
|
|
</b><i>Zagreb, 14 October 1999.</i><br> |
| 212 |
|
|
The Vladimir Prelog Organic Chemistry Award was established in 1996 as a |
| 213 |
|
|
means to encourage young Croatian scientists in the field of organic |
| 214 |
|
|
chemistry. Its founders were PLIVA d.d. and the Croatian Chemical Society. |
| 215 |
|
|
|
| 216 |
|
|
16 PLIVA CEO, Zeljko Covic, named 1999 Emerging Markets CEO of the Year</a><br> |
| 217 |
|
|
</b><i>Zagreb, 28 September 1999.<br> |
| 218 |
|
|
The selection Committee for the 1999 Emerging Markets CEO of the Year |
| 219 |
|
|
Awards has selected Zeljko Covic, President of PLIVA's Management |
| 220 |
|
|
Board, and PLIVA, as the Europe, Middle East and Africa Award |
| 221 |
|
|
winner. |
| 222 |
|
|
15 PLIVA GROUP RESULTS FOR 1H 1999.</a><br> |
| 223 |
|
|
<i>Zagreb, 16 September, 1999.</i><br> |
| 224 |
|
|
Despite challenges in the operating environment (Kosovo crisis, |
| 225 |
|
|
the introduction of<span style="mso-spacerun: yes"> </span>a |
| 226 |
|
|
reference price system and illiquidity in the Croatian health-care |
| 227 |
|
|
sector, introduction of a new health-care system in Poland and the |
| 228 |
|
|
continuation of the Russian crisis), PLIVA achieved good results in |
| 229 |
|
|
the first six months. |
| 230 |
|
|
14 Organisational Changes</a></b><br> |
| 231 |
|
|
<i>Zagreb, 1st July 1999.</i><br> |
| 232 |
|
|
In response to changes in the environment, and with the aim |
| 233 |
|
|
of generating long-term growth, PLIVA has defined a new strategy |
| 234 |
|
|
within the activities of its PLIVA XXI project. The strategy is |
| 235 |
|
|
based on pharmaceuticals being the core-business, continuously |
| 236 |
|
|
increasing R&D investments and intensifying the |
| 237 |
|
|
internationalisation of the company. |
| 238 |
|
|
13 Continued Strong Growth of Zithromax (Azithromycin) Sales</a><br> |
| 239 |
|
|
</b><i>Zagreb, 20th April 1999.</i><b><br> |
| 240 |
|
|
</b>"Global sales of Zithromax (azithromycin), a broad-spectrum |
| 241 |
|
|
oral antibiotic increased by 44 percent to US$ 441 million in the |
| 242 |
|
|
first quarter of 1999", Pfizer reported last week. "Growth |
| 243 |
|
|
in sales resulted form physicians' increasing recognition of the |
| 244 |
|
|
product's broad efficacy, compliance advantages, favourable |
| 245 |
|
|
side-effect profile and, in liquid formulation for children, a |
| 246 |
|
|
pleasant taste. Zithromax continues to be the most prescribed |
| 247 |
|
|
brand-name prescription antibiotic in the U.S," added Pfizer in |
| 248 |
|
|
its Press Release. |
| 249 |
|
|
12 PLIVA announces acquisition of MIXIS GENETICS Ltd.</a><br> |
| 250 |
|
|
</b><i>Zagreb, 15th April 1999.</i><b><br> |
| 251 |
|
|
</b>PLIVA, the largest pharmaceuticals company in Central and |
| 252 |
|
|
Eastern Europe announces that it has acquired 100% ownership of the |
| 253 |
|
|
company MIXIS GENETICS Ltd. ("MIXIS") for US$ 3.3 million. |
| 254 |
|
|
By this transaction PLIVA becomes the owner of several patents |
| 255 |
|
|
covering break-through technologies in the field of biodiversity. |
| 256 |
|
|
11 PLIVA GROUP 1998 FULL YEAR RESULTS</a><br> |
| 257 |
|
|
</b><i>Zagreb, 12th April 1999.</i><b><br> |
| 258 |
|
|
</b>PLIVA, the largest pharmaceuticals company in Central and |
| 259 |
|
|
Eastern Europe and listed on the London and Zagreb Stock Exchanges, |
| 260 |
|
|
today announces excellent full year results for the financial year |
| 261 |
|
|
1998. |
| 262 |
|
|
10 PLIVA AND THE ALTHEXIS COMPANY ANNOUNCE A COLLABORATION ON THE STRUCTURE-BASED DRUG DESIGN OF NOVEL BROAD SPECTRUM ANTIBIOTICS</a><br> |
| 263 |
|
|
</b><i>Zagreb, 8th February 1999.</i><b><br> |
| 264 |
|
|
</b>PLIVA d.d., Zagreb, Croatia and The Althexis Company, Inc., |
| 265 |
|
|
Boston, MA., USA, today announced that they have entered into a |
| 266 |
|
|
collaboration to develop and commercialise novel broad spectrum |
| 267 |
|
|
antibiotics using structure-based drug design ("SBDD") |
| 268 |
|
|
technologies. PLIVA support for the Althexis program may total $14.4 |
| 269 |
|
|
million over three years in research funding and milestone payments. |
| 270 |
|
|
Additional future revenues to Althexis and PLIVA may result from |
| 271 |
|
|
certain exclusive marketing rights each retains under the |
| 272 |
|
|
collaboration agreement. |
| 273 |
|
|
9 PLIVA d.d. ANNOUNCES JOINT RESEARCH VENTURE WITH GLAXO WELLCOME PLC TO FIND NEW ANTIBIOTICS TO BEAT TREATMENT RESISTANCE</a><br> |
| 274 |
|
|
</b><i>Zagreb, 1st February 1999.</i><b><br> |
| 275 |
|
|
</b>PLIVA, the largest pharmaceutical company from Central and |
| 276 |
|
|
Eastern Europe, announces that they are today signing a Memorandum |
| 277 |
|
|
of Understanding with the UK-based pharmaceutical company, Glaxo |
| 278 |
|
|
Wellcome plc, for a research collaboration aimed at finding the next |
| 279 |
|
|
generation of macrolide antibiotics, capable of overcoming the |
| 280 |
|
|
growing problem of treatment resistance. |
| 281 |
|
|
8 INTRODUCING A REFERENCE PRICE SYSTEM FOR PHARMACEUTICAL PRODUCTS IN CROATIA AND ITS INFLUENCE ON PLIVA'S BUSINESS PERFORMANCE</a><br> |
| 282 |
|
|
</b><i>Zagreb, 20 January 1999.</i><b><br> |
| 283 |
|
|
</b>Prompted by the Ministry of Health, the Croatian Institute for |
| 284 |
|
|
Health Insurance ("HZZO") has announced its intention to |
| 285 |
|
|
introduce, as of 01 February 1999, a system of so-called reference |
| 286 |
|
|
prices for all pharmaceutical products reimbursed by state health |
| 287 |
|
|
insurance. Accordingly, PLIVA d.d. ("PLIVA"), the largest |
| 288 |
|
|
pharmaceutical company in Croatia and leading pharmaceutical group |
| 289 |
|
|
in Central and Eastern Europe, has commenced negotiations with the |
| 290 |
|
|
Ministry of Health and HZZO about determining new prices of drugs. |
| 291 |
|
|
7 PLIVA LAUNCHES NEW STRATEGY FOR THE 21st CENTURY</a><br> |
| 292 |
|
|
</b><i>Zagreb, 17 December 1998.</i><b><br> |
| 293 |
|
|
</b>PLIVAs new vision and new strategy represents the companys |
| 294 |
|
|
response to the challenges that globalisation is setting before |
| 295 |
|
|
pharmaceutical companies. At the same time, it represents an |
| 296 |
|
|
adjustment to the times and circumstances which characterise this |
| 297 |
|
|
industry at the end of the 90s and will depict the trends in the |
| 298 |
|
|
next decade. |
| 299 |
|
|
|
| 300 |
|
|
6 PLIVA TO BUY POLISH PHARMACEUTICAL COMPANY FARMACOM</a><br> |
| 301 |
|
|
</strong><i>Zagreb, 14 December 1998.</i><strong><br> |
| 302 |
|
|
The Memorandum of Understanding deals with PLIVA's |
| 303 |
|
|
intention to purchase a 60% stake in the Polish pharmaceutical |
| 304 |
|
|
company FARMACOM whose head office is situated in Krakow, Poland. |
| 305 |
|
|
5 <strong>POLFA KRAKOW CHANGES NAME TO PLIVA KRAKOW</strong></a><br> |
| 306 |
|
|
<i>Zagreb, 14 December 1998.</i><br> |
| 307 |
|
|
POLFA Krakows General Assembly decided to change the name of the |
| 308 |
|
|
company at its meeting held on 30 November 1998. The new name - |
| 309 |
|
|
PLIVA Krakow - will be officially used after completion of legal |
| 310 |
|
|
procedures dealing with the registration which will be carried out |
| 311 |
|
|
at the Polish court with jurisdiction over the matter. |
| 312 |
|
|
|
| 313 |
|
|
4 <strong>PLIVA AND PRIVREDNA BANKA ZAGREB SIGN COMMERCIAL PAPER CONTRACT</strong></a><br> |
| 314 |
|
|
<i> |
| 315 |
|
|
Zagreb, 11th December 1998.</i> |
| 316 |
|
|
On 11 December 1998, |
| 317 |
|
|
PLIVA, the leading pharmaceutical company from Central and Eastern |
| 318 |
|
|
Europe, signed a contract with Privredna banka Zagreb for issuing |
| 319 |
|
|
and selling PLIVAs commercial papers on the Croatian money |
| 320 |
|
|
market. The contract defines a HRK 400 million commercial paper |
| 321 |
|
|
programme. |
| 322 |
|
|
|
| 323 |
|
|
3 <strong>PLIVA SIGNS A USD 100 MILLION WORTH EURO-COMMERCIAL PAPER PROGRAM</strong></a><br> |
| 324 |
|
|
Zagreb, 4th December 1998</i><i>.</i> |
| 325 |
|
|
<br> |
| 326 |
|
|
PLIVA, the largest |
| 327 |
|
|
pharmaceutical company from Central and Eastern Europe signs a USD |
| 328 |
|
|
100 million worth Euro-commercial paper program and gain |
| 329 |
|
|
access to the debt marketIn Vienna on Friday 4 December, PLIVA |
| 330 |
|
|
signed a contract with six European banks which allows it to issue |
| 331 |
|
|
Euro commercial papers up to USD 100 million on the Euro market. |
| 332 |
|
|
2 RESPONSE TO SPECULATION RELATING TO LEK |
| 333 |
|
|
Zagreb, 5th October 1998 |
| 334 |
|
|
PLIVA, the largest |
| 335 |
|
|
pharmaceutical company from CEE, today denied the press speculation |
| 336 |
|
|
that it may be intending to make a hostile takeover bid for Lek, the |
| 337 |
|
|
Slovenian pharmaceutical company based in Ljubljana. |
| 338 |
|
|
1 PLIVA ACQUIRES WORLD-WIDE RIGHTS FOR A NEW COMPOUND WITH THROMBOPOIETIN-LIKE ACTIVITY |
| 339 |
|
|
Zagreb, 7th September 1998.</small></i> |
| 340 |
|
|
The action of the |
| 341 |
|
|
compound is distinctly different from thrombopoietin and constitutes |
| 342 |
|
|
a strong alternative or complement to thrombopoietin . |
| 343 |
|
|
|
| 344 |
|
|
0 1998 HALF YEAR RESULTS - CONTINUED STRONG PERFORMANCE<br> |
| 345 |
|
|
Zagreb, 4th September 1998. |
| 346 |
|
|
OPERATING PROFIT UP BY 28.6% PLIVA, the largest pharmaceutical company in Central & |
| 347 |
|
|
Eastern Europe, listed on the London and Zagreb Stock Exchanges, |
| 348 |
|
|
today announced excellent results for the first half of 1998. |
| 349 |
|
|
-1 PLIVA OPENS NEW STATE-OF-THE-ART AZITHROMYCIN PRODUCTION FACILITY</b><br> |
| 350 |
|
|
</a><i>Zagreb, 4th September 1998</i><i>.</i><br> |
| 351 |
|
|
PLIVA, the largest pharmaceutical company in Central |
| 352 |
|
|
and Eastern Europe, announces that its new Azithromycin production |
| 353 |
|
|
plant has been completed. The project worth US$ 100 million is |
| 354 |
|
|
PLIVAs biggest investment in a production site to date. A major |
| 355 |
|
|
part of the investment has been financed by PLIVAs own funds. |
| 356 |
|
|
-2 PLIVA ACQUIRES YEAST FACTORY IN SLOVAKIA</b><br> |
| 357 |
|
|
</a><i>Zagreb, 4th September 1998</i><i>.<br> |
| 358 |
|
|
PLIVA, the largest pharmaceutical company from Central and |
| 359 |
|
|
Eastern Europe, announces the acquisition of Fermenta, joint stock |
| 360 |
|
|
company in Trebiov, Slovakia ("Fermenta"). Fermenta, the |
| 361 |
|
|
second biggest Slovakian yeast producer, was purchased for a cash |
| 362 |
|
|
consideration of USD 1.3 million. |
| 363 |
|
|
|
| 364 |
|
|
-3 SECONDARY OFFERING OF PLIVA SHARES:<br> </small><small>I</small><small><small>NSTITUTIONAL PRICE FIXED AT US$ 16.60 PER GDR</small><br> STRONG INTERNATIONAL AND DOMESTIC DEMAND SHOWN</small> |
| 365 |
|
|
</b><i>Zagreb, 13th May 1998.</i><small><br> |
| 366 |
|
|
The Croatian Ministry of Finance today announced the successful |
| 367 |
|
|
completion of an offering of approximately 2.92 million shares |
| 368 |
|
|
(which includes 12.37 million GDRs) of PLIVA |
| 369 |
|
|
d.d. (PLIVA). |
| 370 |
|
|
PLIVA |
| 371 |
|
|
is the most profitable company in Croatia and the largest |
| 372 |
|
|
pharmaceutical company headquarters in Central and Eastern Europe. |
| 373 |
|
|
-4 PLIVA SIGNS AGREEMENT WITH WARNER-LAMBERT PHARMACEUTICAL RESEARCH TO LICENSE OUT GASTROINTESTINAL PEPTIDES |
| 374 |
|
|
</b><i>Zagreb, 24th April, 1998.</i><b><br> |
| 375 |
|
|
|
| 376 |
|
|
PLIVA, the largest pharmaceutical company in Central and Eastern |
| 377 |
|
|
Europe has signed an agreement with Parke-Davis, a division of |
| 378 |
|
|
Warner-Lambert Company. The agreement gives Parke-Davis an exclusive |
| 379 |
|
|
option to license PLIVAs newly discovered gastrointestinal |
| 380 |
|
|
peptides. |
Parent Directory
| 
Revision Log